Wedbush Raises Ovid Therapeutics PT to $7 from $5, Maintains Outperform Rating

viernes, 20 de marzo de 2026, 8:32 am ET1 min de lectura
OVID--

Wedbush Raises Ovid Therapeutics PT to $7 from $5, Maintains Outperform Rating

Wedbush Raises Ovid Therapeutics PT to $7 from $5, Maintains Outperform Rating

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios